MAG was prepared from delipidated myelin by lithium diodosalicylate and phenol extraction according to Quarles and Pasnak (11) .
Partial NH2Terminal Sequence of IgM Heavy and Light Chains. Monoclonal IgM were isolated from sera by 40% saturated ammonium sulfate precipitation and were purified by gel chromatography followed by preparative zone electrophoresis . IgA, IgG, haptoglobin, and transferrin contaminants were removed on affinity adsorbents . Heavy and light chains were obtained by mild reduction performed with 10 mM 1-4 dithio-Dl-threitol and alkylation with 10% excess of [ 14 G] iodoacetic acid (7.5 . 106 cpm/mol) (Amersham Corp., Amersham, UK); thereafter the chains were separated on a Sephadex Gloo column equilibrated with 1 M acetic acid. The typing of variable regions from heavy and light chains was achieved by Edman sequence degradation, using 4N,N'-dimethylarninoazobenzene-4'isothiocyanate (Fluka, Buchs, Switzerland)/phenyl-isothiocyanate (Pierce Chemical Co., Rockford, IL) double-coupling method followed by thin-layer chromatography (12) .
Antiidiotypic Serum. An adult marmoset was injected with purified IgMROG ; the first immunization was performed subcutaneously in IFA (500 Ag IgM in multiple sites) and booster injections were given every 15 d with IgMRor, resuspended in saline buffer. Bleedings were obtained at monthy intervals and tested by double immunodiffusion against a panel ofmonoclonal anti-MAG IgM and normal serum. Bleedings that reacted strongly with anti-MAG IgM but not or weakly with normal serum were pooled and absorbed on Sepharose 4B beads coupled to normal human serum, polyclonal IgG, or four different monoclonal IgM devoid ofanti-MAG specificity. This marmoset antiidiotypic serum was thereafter studied by ELISA .
ELISA Assays. The reactivity ofmarmoset antiidiotypic serum with anti-MAG or normal IgM was assessed by two ELISA assays . First, microtiter plates (Consortium de Materiel pour Laboratoire, Nemours, France) coated with 1 Ag IgM/well for 18 h were blocked with 3 % BSA in saline and incubated with serial dilutions of marmoset antiidiotypic serum; the binding ofmarmoset IgG was revealed with S-galactosidase-labeled goat antibodies to human IgG (Biosys, Compiegne, France) followed by substrate . No reactivity was recorded when the addition of marmoset antiidiotypic was omitted or when nonimmune marmoset serum was used. A similar assay was performed on plates coated with 10 l~g/well of purified A, K, or X chains .
Alternatively, monoclonal IgM were incubated for 12 h on plates precoated with 1 wg/well of mouse mAb to t~h eavy chain . Thereafter, marmoset antiidiotypic antibody was added at a 10-1 dilution and the assay was developed with phosphatase alkaline-conjugated purified goat IgG to human (and primate) .y chains (Caltag Laboratory, San Francisco, CA) absorbed on mouse Ig, followed by substrate .
Inhibition experiments were performed as follows : anti-A precoated plates were incubated with 5 Rg/well IgMDEp and revealed by marmoset antiidiotypic antibody (1/30 final dilution) previously incubated for 12 h with various amounts (10-2 to 102 l~g) of anti-MAG or of an irrelevant monoclonal IgM followed by phosphatase alkaline-conjugated purified goat antibodies to human y chains and substrate.
In other experiments, glutaraldehyde-pretreated plates were incubated with 10 Ag ofpurified MAG, blocked with L-lysine and various amounts of anti-MAG IgM previously incubated for 18 h with a 1/50 final dilution of marmoset antiidiotypic serum were added. Plates were revealed with a-galactosidase-labeled goat antibodies to human l~c hains followed by substrate (Biosys).
Results
Specificity of Marmoset Antiidiotypic Serum. As evidenced by immunoblotting experiments, the 10 IgM studied reacted with 90/100-kD polypeptides of myelin corresponding to MAG. In addition, IgM bound to purified MAG by immunoblotting or ELISA assays (not shown) .
As shown in Fig served with irrelevant monoclonal IgM. Inhibition studies confirmed the existence of crossidiotopes between IgM (Fig. 2 A) since the fixation of marmoset antiidiotypic serum to IgMDEP (i.e., an IgM different from that used for immunization) was completely inhibited in the presence ofanti-MAG IgM studied but was unaffected by an irrelevant IgMLEC . At least some of the shared idiotopes appeared to be related to the combining site of the IgM since incubation of four IgM with marmoset antiidiotypic serum inhibited their binding to MAG by ELISA (Fig. 2 B) . In similar experiments, rabbit antisera to anti-MAG IgM that recognized private or semipublic idiotopes were not inhibitory (7; and unpublished data).
Marmoset antiidiotypic serum did not react either with isolated heavy and light chains from the six anti-MAG IgM tested or with variable subgroup matched ' u chains or purified light chains (Fig. 1 B) . Finally, various marmoset bleedings were tested by fluorescence on nerve sections for the presence of anti-antiidiotypic (ab3) antibodies : none were found, even in late bleedings after the end ofbooster immunizations.
NH2 Terminal Sequence of Heavy and Light Chairs ofAnti-MAG IgM. Of seven IgM studied, only one possessed X chains (AZI) with a Vxtt variable region. Three K chains (DEP, FUE, and LOC) belonged to the VKIV subgroup with characteristic amino acids at position 9 and 12 (13) . Two K chains (BOU and BLA) were assigned to the V,,l subgroup, although several mutations existed in comparison to prototype sequence (Table I) since they had the relatively invariant amino acids of VKI subgroup at position 3 and 13 and none ofthe characteristic amino acids ofthe other subgroups. Finally, IgM PEC belonged to the VK1I subgroup as shown by its NH2-terminal sequence and the finding of an invariant methionine at position 89 . Heavy chain NH2-terminal amino acid sequence allowed the assignment to the VH111 subgroup of 6 p. chains whose 10 first residues were identical to that of the VHIII Gal prototype sequence (13) . IgM AZI belonged to the VHII subgroup with a single amino acid substitution at position 7 (threonine for serine) when compared with the OU prototype sequence. Discussion Monoclonal IgM directed to MAG and nerve glycolipids recently attracted much interest since they may mediate the first instance of human autoimmune peripheral neuropathy. Although this matter remains controversial, intraneural injections of anti-MAG IgM as well as passive transfer experiments support this possibility (reviewed in reference 14). So far the antigenic and biochemical features of these IgM remain poorly characterized.
We show here that a primate antiserum to human anti-MAG IgM contains antibodies to a combining site-related public crossidiotype carried by 9 of 10 IgM tested. This antiserum was able to block the binding ofmonoclonal IgM to MAG and reacted with several IgM having K or X chains and 1A heavy chain belonging to VHIII (all IgM tc) or VHII (one IgM X) subgroups. In addition, inhibition studies suggested that all reactive IgM share a similar set of idiotopes. This marmoset antiidiotypic serum most likely recognizes conformational epitope(s) since it was unreactive with isolated light and heavy chains. These results contrast with those from previous reports where only private or highly restricted idiotypes were disclosed by rabbit polyclonal antisera and mouse mAbs antibodies (3-8; and unpublished data). The reasons for this discrepancy are not readily apparent . Of note, mouse and rabbit MAG are unreactive with human anti-MAG IgM and possibly the repertoire of these animals is submitted to idiotypec regulation depending on the structure ofselfantigens. Such species-restricted ab2 response have already been observed for RF (15) . On the other hand, structural data (see below) showed that the combining site of these IgM is most often composed of VHIII-related heavy chains paired with K chains belonging to different subgroups of variability. Therefore, epitopes exposed at the surface of the IgM and that are immunogeneic in these species may be different from one IgM VKt
to the other. In either instance, more related species, such as nonhuman primates, could more easily recognize human anti-MAG IgM combining sites. That such broadly crossreactive antiidiotypic antibodies are mostly directed against epitope(s) involved in (or close to) the combining site is not unexpected in view of the highly restricted specificity of anti-MAG IgM for a glucuronyl sulfated epitope of the carbohydrate moiety ofMAG and peripheral nerve glycolipid SGPG (9, 10) . However, slight differences in the fine specificity of anti-MAG IgM may exist (16, 17) , and could account for the variable levels of binding to marmoset antiidiotypic serum of different anti-MAG IgM. Dissection of the antigenic and structural relationship between individual monoclonal RF or CA in humans revealed that only a limited number of germline genes undergoing relatively few somatic mutations contribute to the generation of these monoclonal antibodies (18) (19) (20) . Strikingly, a majority ofmonoclonal RF or CA possess light chains belonging to the VHIII subgroup. Most of them derive from a single (Hum 325) or closely related variable K genes. Since other autoantibodies use also VKHIb-related genes (21), a model for autoantibody generation has been proposed where the binding specificity is defined by the variable segment ofheavy chains paired with multipotential light chains (18) . Obviously anti-MAG IgM do not fit within this scheme ; light chains from these IgM indeed belong to different VK variability subgroups (VKI, VKII, VKIv) and none are related to the Von subgroup so far. Interestingly half of the K chains studied belong to the rare VKIv subgroup, which is associated with <5% of sequenced light chains and coded by a single germline VKIv gene.
These various light chains of anti-MAG were associated in all but one instance to VHIII-derived IL heavy chains . Such a restriction of heavy chain variable regions is consistent with previous data for both RF and CA. However, at least three different VHI variable genes are used by the RF belonging to the Wa CRI group and limited structural studies showed that salient features were the use of a JH4 region and of DH regions of uniform size (22) . Therefore, more structural data are needed to attain meaningful conclusions.
Altogether the present results indicate that anti-MAG IgM exhibit distinct antigenic and structural features as compared with those of other monoclonal IgM with a defined antibody activity. Whether or not they correspond to different pathogenetic processes (antigen-driven autoantibodies versus spontaneous production of autoantibodies from germline genes with few somatic mutations) presently remains speculative. Summary Most studies using rabbit or mouse antisera failed to detect CRI between human IgM directed to MAG. We show here that 9 of 10 such IgM express a public CRI as defined by a nonhuman primate antiserum. Shared idiotype is likely involved in (or close to) the combining site of those IgM since antiidiotypic serum inhibited the binding of IgM to MAG and reacted with IgM having different variable regions oflight and heavy chains . Partial aminoterminal sequence ofheavy and light chains showed that anti-MAG IgM use either X chains (one IgM) or K light chains (six IgM) of different variability subgroups (VKIv in three instances, VKI in two, and VKII in one), whereas heavy chains belong to the VHIII (six IgM) or to the VHII (1 IgM) subgroup. These features distinguish these IgM from other human monoclonal IgM with a defined antibody activity, such as rheumatoid factors or cold agglutinins .
